Composition and uses thereof
US-2016144011-A1 · May 26, 2016 · US
Adenovirus vectors
US10124048B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10124048-B2 |
| Application number | US-201514697373-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 27, 2015 |
| Priority date | Apr 10, 2007 |
| Publication date | Nov 13, 2018 |
| Grant date | Nov 13, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An adenoviral vector comprising a promoter further comprising a fragment of the 5′ untranslated region of the CMV IE1 gene including intron A and a nucleic acid sequence encoding a pathogen or tumor antigen for use as a medicament.
First claim
Opening claim text (preview).
The invention claimed is: 1. An adenoviral vector comprising a promoter and a nucleic acid sequence encoding an antigen from a pathogen or a tumour antigen under the control of said promoter, wherein said promoter consists of SEQ ID NO: 7, and wherein said antigen is not a murine malaria parasite antigen. 2. The adenoviral vector according to claim 1 , wherein the adenoviral vector is a simian adenoviral vector. 3. The adenoviral vector according to claim 1 , wherein the adenoviral vector is AdC6 (C6), AdC7 (C7), or AdC9 (C9) vector. 4. An immunogenic composition comprising the adenoviral vector of claim 1 admixed with one or more pharmaceutically acceptable vehicles, carriers, diluents, or adjuvants. 5. A product, combination or kit comprising; a) a priming composition comprising the adenoviral vector according to claim 1 ; and b) a boosting composition comprising a recombinant pox virus vector, said pox virus vector further comprising at least one nucleic acid sequence encoding a pathogen or tumour antigen which is the same as the antigen of the priming composition. 6. The product, the combination or the kit according to claim 5 , wherein the promoter excludes Exon B of the CMV IE1 gene. 7. A composition comprising the immunogenic composition according to claim 4 and a CpG adjuvant.
Assignees
Inventors
Classifications
CpG containing adjuvants; Oligonucleotide containing adjuvants · CPC title
Antineoplastic agents · CPC title
Kit · CPC title
characterised by the dose, timing or administration schedule · CPC title
viral genome or elements thereof as genetic vector · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10124048B2 cover?
- An adenoviral vector comprising a promoter further comprising a fragment of the 5′ untranslated region of the CMV IE1 gene including intron A and a nucleic acid sequence encoding a pathogen or tumor antigen for use as a medicament.
- Who is the assignee on this patent?
- Isis Innovations Ltd, Univ Oxford Innovation Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K39/015. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).